Filters: keyword is Aged [Clear All Filters]
- 2008
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients,
Clin Pharmacol Ther, vol. 83, no. 3, pp. 443-51.
Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients,
Eur J Clin Pharmacol, vol. 64, no. 3, pp. 329-34.
Prediction of attack frequency in migraine treatment,
Cephalalgia, vol. 28, no. 8, pp. 847-55.
- 2006
Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients,
Eur J Clin Pharmacol, vol. 62, no. 3, pp. 185-94.
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus,
J Pharmacokinet Pharmacodyn, vol. 33, no. 3, pp. 313-43.
- 2005
Allometric relationships between the pharmacokinetics of propofol in rats, children and adults,
Br J Clin Pharmacol, vol. 59, no. 6, pp. 705-11.
Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment,
J Control Release, vol. 101, no. 1-3, pp. 199-208.
Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration,
Am J Kidney Dis, vol. 45, no. 2, pp. 360-71.
Cutaneous side-effects of transdermal iontophoresis with and without surfactant pretreatment: a single-blinded, randomized controlled trial,
Br J Dermatol, vol. 153, no. 2, pp. 404-12.
- 2004
Long-term sedation with propofol 60 mg ml(-1) vs. propofol 10 mg(-1) ml in critically ill, mechanically ventilated patients,
Acta Anaesthesiol Scand, vol. 48, no. 3, pp. 302-7.
Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients,
Br J Clin Pharmacol, vol. 57, no. 2, pp. 135-45.
Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro,
J Control Release, vol. 96, no. 1, pp. 159-67.
- 2002
Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%,
Clin Pharmacol Ther, vol. 72, no. 6, pp. 670-84.
- 2000
A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias,
Braz J Med Biol Res, vol. 33, no. 2, pp. 199-204.
A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep,
Clin Pharmacol Ther, vol. 68, no. 2, pp. 175-88.
Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery,
Eur J Clin Pharmacol, vol. 56, no. 1, pp. 89-95.
- 1999
Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN,
Pharm World Sci, vol. 21, no. 5, pp. 239-40.
Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection,
Br J Clin Pharmacol, vol. 47, no. 6, pp. 653-60.
- 1998
Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease,
Clin Neuropharmacol, vol. 21, no. 3, pp. 159-68.
Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease,
Clin Neuropharmacol, vol. 21, no. 3, pp. 152-8.
- 1997
A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population,
Br J Clin Pharmacol, vol. 44, no. 3, pp. 267-75.
Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep,
Clin Pharmacol Ther, vol. 62, no. 4, pp. 444-52.
Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass,
Braz J Med Biol Res, vol. 30, no. 3, pp. 369-74.
- 1996
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease,
Mov Disord, vol. 11, no. 6, pp. 633-8.
- 1995
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories,
Mov Disord, vol. 10, no. 4, pp. 433-9.



